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ABSTRACT  
Heparanase is a heparan sulfate (HS) degrading endoglucuronidase that has been 
implicated in cell migration and inflammatory conditions. Here we used mice 
deficient of heparanase (Hpse
-/-) to study the impact of heparanase on airway 
leukocytes. Normal numbers of macrophages and lymphocytes were present in 
bronchoalveolar lavage fluid of Hpse-/- mice, indicating that heparanase is not 
essential for proper homing of leukocytes to airways. While lymphocytes from 
Hpse
-/- mice displayed normal morphology, Hpse
-/- alveolar macrophages showed a 
striking, age-dependent appearance of granule-like structures in the cytoplasm. 
Transmission electron microscopy revealed that these structures corresponded to 
membrane-enclosed crystalline bodies that closely resembled the intracellular 
crystals known to be formed by the HS-binding protein Ym1, suggesting that 
heparanase deficiency is associated with intracellular Ym1 deposition. Indeed, 
applying immunocytochemistry, we found markedly higher levels of intracellular 
Ym1 protein in Hpse
-/- versus WT alveolar macrophages, and there was a 
significant correlation between levels of Ym1 protein detected by immunoblotting 
and amounts of crystalline material in BAL cells. Biosynthetic radio-labeling of 
the macrophages revealed accumulation of non-degraded HS chains in Hpse
-/- 
alveolar macrophages. Together, these findings implicate heparanase in normal 
processing of HS in macrophages, and indicate that heparanase regulates 
intracellular Ym1 accumulation and crystal formation in airways.  
 
Keywords: heparanase knockout mice; heparan sulfate; chitinase-like protein; 
alveolar macrophages; airway inflammation 
   3 
Abbreviations: BAL, bronchoalveolar lavage; BMMØ, bone marrow-derived 
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GAG, glycosaminoglycan; Hpse, heparanase; HS, heparan sulfate; HSPG, heparan 
sulfate proteoglycans; TEM, transmission electron microscopy.   4 
1. Introduction 
 
Heparan sulfate proteoglycans (HSPGs) consist of protein cores to which sulfated 
and thereby negatively charged glycosaminoglycans (GAGs) of heparan sulfate 
(HS) type are attached. HSPGs are ubiquitously expressed, being present on the 
cell surface of most cell types as well as being one of the main components of the 
extracellular matrix (ECM). Cell surface HSPGs, e.g. of the syndecan or glypican 
families (Alexopoulou et al., 2007; Filmus et al., 2008), mediate cell-cell and cell-
matrix contacts and function as co-receptors for various growth factors (Mythreye 
and Blobe, 2009). In addition, cell surface HSPGs lining the vascular endothelium 
act as sites for leukocyte attachment, thereby facilitating migration of blood-borne 
cells into tissues (Wang et al., 2005).  
 
Heparanase is an endoglucuronidase that cleaves HS chains (Pikas et al., 1998). 
Heparanase may thus modify the structure of preformed HSPGs and hence regulate 
the plethora of processes in which HSPGs are implicated. Indeed, previous studies 
have suggested a role for heparanase in various pathophysiological conditions, 
including tumor metastasis (Escobar Galvis et al., 2007; Vlodavsky and 
Friedmann, 2001), experimental autoimmune disease (Lider et al., 1989), 
amyloidosis (Li et al., 2005) and delayed type hypersensitivity (DTH) reactions 
(Edovitsky et al., 2006). A role for heparanase in tumour metastasis is supported 
by the strong correlation between levels of heparanase expression and metastatic 
potential of B16 melanoma (Vlodavsky et al., 1999) and T lymphoma (Goldshmidt 
et al., 2002b) cells. Further, it has been shown by RNA interference that 
suppression of heparanase expression ameliorates DTH reactions (Edovitsky et al.,   5 
2006) as well as reduces lung colonization of B16 melanoma cells (Edovitsky et 
al., 2004). The role of heparanase in normal cell and tissue physiology is however 
not well characterized, although a role in tissue remodeling, vascularization and 
hair growth has been suggested applying transgenic mice overexpressing 
heparanase (Zcharia et al., 2004).  
 
It is important to point out that most of the functional implications for heparanase 
have been derived from correlative or in vitro observations, and that detailed 
investigations of the in vivo function of heparanase have been hampered by the 
lack of relevant tools. The recent generation of a mouse strain lacking heparanase 
expression has opened new possibilities for determining its in vivo function 
(Zcharia et al., 2009). Heparanase deficient (Hpse
-/-) mice do not demonstrate any 
major abnormalities under normal conditions, possibly due to an increased 
expression of matrix metalloproteases, compensating for the loss of heparanase-
mediated ECM degradation (Zcharia et al., 2009). Moreover, heparanase 
deficiency results in accumulation of non-degraded HS chains in different tissues. 
 
Heparanase is highly expressed by numerous types of tumor cells, and by various 
cells of the immune system (Vlodavsky et al., 1992), including mast cells (Gong et 
al., 2003), eosinophils (Temkin et al., 2004), dendritic cells (Benhamron et al., 
2006) and monocytes/macrophages (Sasaki et al., 2004). However, the role of 
heparanase in the context of immune cell function is only partially understood. 
Here we addressed this issue by studying the impact of heparanase deficiency on 
various leukocyte populations present in airways. We show that the absence of 
heparanase does not affect homing of lymphocytes or macrophages into the   6 
airways, nor does it affect lymphocyte morphology. However, lack of heparanase 
caused an accumulation of Ym1, a chitinase-like protein, accompanied by a 
striking appearance of intracellular crystalline bodies in alveolar macrophages. 
Moreover, the HS chains in heparanase mutant macrophages were longer than in 
WT macrophages. Together, these findings implicate heparanase in the regulation 
of macrophage homeostasis.    7 
2. Materials and Methods 
 
2.1. Mice and collection of bronchoalveolar lavage 
Heparanase-deficient (Hpse
-/-) mice were generated as described (Zcharia et al., 
2009) and were bred and maintained in the animal facility at Uppsala Biomedical 
Centre. Experimental groups were age and sex matched and Hpse
+/+ littermates 
(WT mice) were used as controls. All animal experiments were approved by the 
local ethical committee. Bronchoalveolar lavage (BAL) fluid was collected by 
rinsing the lungs twice with 1 ml HBSS. Total numbers of cells were counted and 
cytospin slides were prepared. In separate experiments the remaining cells were 
centrifuged and prepared for TEM or immunoblot analysis, and the cell-free BAL-
supernatants were stored in -20° until used. 
 
2.2. Transmission electron microscopy (TEM) 
BAL cells from 7 or 17 months old Hpse
-/- and WT mice were pooled from 2 mice 
per group and prepared for TEM as described (Braga et al., 2007). Electron 
micrographs were generated using a Hitachi electron microscope (Hitachi Ltd., 
Tokyo, Japan) (Lukinius et al., 1995).  
 
2.3. Differential cell count and morphology 
Cytospin slides were stained with May-Grünwald/Giemsa (Merck, Darmstadt, 
Germany) and the numbers of different airway cells were determined by 
differential counting of at least 200 cells per slide. The altered morphology of 
alveolar macrophages, i.e. the presence of granules in the cytoplasm, was 
quantified by blinded scoring of at least 200 cells per slide. Cells with visual   8 
granules were given scores (1-3) corresponding to the degree of granulation and no 
score (0) was given for cells lacking granules. An average score per counted cell 
was determined. To evaluate the presence of highly sulfated GAGs, cells were 
stained with Toluidine blue or Alcian blue as described (Braga et al., 2007; Reimer 
et al., 2006).  
 
2.4. Immunocytochemistry  
For immunocytochemistry, cytospin slides were fixed in ice-cold acetone for 5 
minutes. Cells were permeabilized and blocked by incubation for 30 minutes with 
PBS containing 0.1% saponin, 0.5% BSA, and 10% goat serum. Endogenous 
peroxidase was blocked with PBS containing 0.3% H2O2 and 0.3% goat serum for 
5 minutes. Cells were stained for 1 hr with anti-Ym1 antibodies (StemCell 
Technologies, Vancouver, Canada) or anti-mouse IgG (H+L) antibodies 
(Chemicon international, Temecula, CA, USA) diluted 1:200 in a blocking buffer 
(PBS with 0.1% saponin, 0.5% BSA, 2% goat serum, and 0.42mM NaCl). Rabbit 
IgG (Vector Laboratories, Burlingame, CA, USA) was used as a negative control. 
Cells were then incubated for 1 hr with biotinylated goat anti-rabbit IgG diluted 
1:200 in blocking buffer. The Vectastain® Elite ABC reagent and DAB substrate 
kit for peroxidase were used for development (Vector Laboratories). Slides were 
counterstained for 2 minutes with Mayer’s hematoxylin solution (Sigma-Aldrich, 
St. Louis, MO, USA) and mounted with VectaMount (Vector Laboratories).  
 
2.5. Generation of bone marrow derived macrophages 
To generate conditioned medium for macrophage differentiation, we cultured the 
colony stimulating factor (CSF)-1 secreting cell line L929 (provided by Dr Ulrich   9 
Blank, Inserm U699, Paris, France) in DMEM supplemented with 5% FCS, 50 
µg/ml penicillin, 60 µg/ml streptomycin and 2mM L-glutamine (SVA, Uppsala, 
Sweden). Culture densities were initially 3x10
5 cells/ml, and after 8 days of 
culture, supernatants were collected, filtered and stored at -20°C until used. Bone 
marrow cells from eight months old WT or Hpse
-/- mice were collected from 
femura and tibia by flushing the bones with 2.5 ml PBS. Red blood cells were 
removed by incubating cells for 2 minutes in 200 µl lysis buffer (0.15M NH4Cl, 
0.1mM EDTA, pH7.4). Cells were cultured overnight in complete medium 
(DMEM supplemented with 15% FCS, 10% L929-conditioned medium, 50 µg/ml 
penicillin, 60 µg/ml streptomycin and 2mM L-glutamine). Non-adherent cells, 
including monocyte precursors, were collected and 3x10
5 cells/ml were added to 
Petri dishes and cultured for 10 days in complete medium before used in further 
analyses.  
 
2.6. FACS analysis 
To confirm the purity of bone marrow derived macrophages, flow cytometry was 
used to identify presence of cells expressing the macrophage marker CD11b. Cells 
were washed twice in PBS and diluted in flow cytometry buffer (0.5%FCS/PBS). 
Samples of 0.2 x 10
6 cells were stained for 30 minutes on ice with 0.5µg PE-
labeled anti-CD11b antibodies or with 0.5µg PE-labeled isotype controls 
(ImmunoTools, Friesoythe, Germany). After washing two times, cells were 
analyzed using a FACScan® flow cytometer and the CELLQuest
TM 3.3 software 
(Becton Dickinson, San Jose, CA, USA).  
 
2.7. Biosynthetic labeling and analysis of HS   10 
Bone marrow derived macrophages from WT or Hpse
-/- mice were cultured at 
0.56x10
6 cells/ml in sulfate free medium supplemented with 2 mM L-glutamine, 
1% pest, 10% L929-conditioned medium, 10% FCS (dialyzed against PBS), and 
100 µCi/ml Na
35SO4 (specific activity 1,500 Ci/mmol; PerkinElmer, Waltham, 
MA, USA). After 24 hours, HS was isolated from medium or cell lysates as 
described (Escobar Galvis et al., 2007). The purified 
35S-labeled HS was analyzed 
on a superose-6 column (GE Healthcare Biosciences, Uppsala, Sweden) in a buffer 
of 0.5M NH4HCO3. 
 
2.8. Immunoblot analysis 
Ten µl of BAL fluid or BAL cell pellets from 13-17 months old WT or Hpse
-/- mice 
were separated under reducing conditions on 12% SDS-PAGE gels. Proteins were 
subsequently blotted onto polyvinylidene difluoride membranes, followed by 
incubation with LI-COR blocking buffer (LI-COR Biosciences, Cambridge, UK) 
for 1h at room temperature. Membranes were stained o.n. at 4°C with anti-Ym1 
(StemCell Technologies) antibodies diluted 1:1000 in blocking buffer. After 
washing with 0.1% Tween 20 in TBS, the membrane was incubated with IR Dye 
800-conjugated donkey anti-rabbit Ig (LI-COR Biosciences, dilution 1:1000) in 
blocking buffer. Visualization and densitometry analyses were performed using 
Odyssey IR imaging system (LI-COR Biosciences). Data were measured as 
counts/mm
2 and normalized to the loading control, i.e. results are expressed as the 
ratio between sample value for Ym1 and the corresponding value for β-actin. 
 
2.9. Statistical analyses   11 
Statistical differences between WT and Hpse
-/- mice were determined by Mann-
Whitney U test, and correlations were analyzed by Spearman test, using the 
GraphPad Prism 4.0 (GraphPad Software, Inc, San Diego, CA, USA).  
   12 
3. Results 
 
3.1. Normal homing of leukocytes to airways in the absence of heparanase 
Heparanase has previously been implicated in inflammatory processes and cell 
migration (Benhamron et al., 2006; Edovitsky et al., 2006; Sasaki et al., 2004), 
although the precise impact of heparanase on leukocyte populations in vivo has not 
been evaluated. To address this issue, we examined the effect of heparanase 
deficiency on leukocytes present in bronhcoalveolar lavage (BAL) fluid. As shown 
in Fig 1A, the BAL cell populations from both WT and Hpse
-/- mice were mainly 
composed of macrophages. There were very few lymphocytes (1.3% in average) 
and almost no neutrophils or eosinophils in BAL, indicating that there was no 
spontaneous ongoing inflammatory reaction in the airways. There was a tendency 
for higher numbers of macrophages and lymphocytes in the Hpse
-/- mice, but the 
difference between WT and Hpse
-/- mice did not reach statistical significance (Fig. 
1A). These results demonstrate that, under normal conditions, heparanase has no 
major impact on migration of macrophages and lymphocytes to the airway lumen. 
 
3.2. Granule-like structures in Hpse
-/- alveolar macrophages 
Examination of the morphology of May-Grünwald/Giemsa-stained BAL leukocyte 
populations showed that Hpse
-/- lymphocytes did not differ morphologically from 
the corresponding WT cells (not shown). In contrast, Hpse
-/- macrophages showed 
a striking presence of purple-stained intracellular, granule-like structures, which 
was not seen in WT macrophages (Fig. 1B). A systematic scoring for the presence 
of granule-like structures in alveolar macrophages from 3-17 months old WT and 
Hpse
-/- mice showed that the extent of granulation correlated strongly with the age   13 
of animals, with a more pronounced granulation seen in old (i.e. 7 and 13-17 
months) vs. young (i.e. 3 months) mice (Fig. 1B and C). Although some signs of 
granulation were also seen in alveolar macrophages from old WT mice, the extent 
and intensity of granulation was markedly higher in corresponding macrophages 
derived from Hpse
-/- mice (Fig. 1B and C). Notably, granule-like structures were 
not seen in peritoneal macrophages from WT or Hpse
-/- mice (not shown), 
suggesting that this phenotype was restricted to the airways.  
 
Potentially, the increased granulation of alveolar macrophages might be associated 
with accumulation of cellular HS due to the absence of heparanase. To address this 
possibility, we stained for sulfated GAGs using Alcian blue and Toluidine blue 
(Fig. 2). Compared with peritoneal macrophages, alveolar macrophages stained 
more intensely with Alcian blue (Fig. 2A), suggesting a higher level of cell-
associated GAGs in airways as compared to peritoneal macrophages. However, 
there was no significant difference in the staining intensity between WT and Hpse
-/- 
macrophages. Moreover, alveolar macrophages did not demonstrate metachromatic 
staining with Toluidine blue (Fig. 2B), indicating that there was no substantial 
accumulation of highly sulfated GAGs in these cells.  
 
3.3. Needle-shaped crystalline bodies in Hpse
-/- alveolar macrophages 
To further examine the nature of the granule-like structures present in Hpse
-/- 
macrophages, alveolar macrophages were examined by transmission electron 
microscopy (TEM). The TEM analysis revealed a striking morphology of electron 
dense and needle-shaped crystalline bodies in alveolar macrophages derived from 
Hpse
-/- animals, structures that were totally absent in corresponding WT cells (Fig.   14 
3). The crystalline bodies were surrounded by membranes, indicating that they had 
developed within membrane-enclosed organelles such as lysosomes, ER or Golgi.  
 
3.4. Accumulation of Ym1 in alveolar macrophages from Hpse
-/- mice 
Next, we sought to identify the macrophage-associated crystalline material. 
Alveolar macrophages constitutively express Ym1, a chitinase-like protein that 
previously has been demonstrated to exhibit a marked tendency to spontaneously 
form crystals in vitro (Chang et al., 2001). Moreover, Ym1 is known to form 
needle-shaped intracellular crystals (Harbord et al., 2002; Nio et al., 2004) that 
closely resemble the crystals found in Hpse
-/- alveolar macrophages (Fig. 3). 
Hence, one plausible scenario is that the crystalline bodies seen in Hpse
-/- alveolar 
macrophages contain Ym1. To address this possibility, we applied 
immunocytochemistry to stain for Ym1 in alveolar and peritoneal macrophages 
from WT and Hpse
-/- mice. As shown in Fig. 4A and B, alveolar macrophages from 
both WT and Hpse
-/- mice stained positively for Ym1 whereas peritoneal 
macrophages were negative, in agreement with the reported absence of Ym1 in un-
stimulated peritoneal macrophages (Hung et al., 2002). However, Hpse
-/- 
macrophages stained considerably stronger for Ym1 than did corresponding WT 
cells, indicating that Hpse deficiency indeed results in accumulation of cell-
associated Ym1. Noteworthy, the staining showed a patchy, intracellular 
appearance, compatible with the presence of Ym1 within membrane-enclosed 
organelles (Fig 4A).  
 
Although Ym1 is a likely candidate to explain the altered morphology of Hpse
-/- 
alveolar macrophages, there are other known crystal-forming proteins to consider.   15 
Of particular interest are immunoglobulin (Ig) light and heavy chains, which are 
known to occasionally form needle-shaped intracellular crystals in tissue 
macrophages of patients with lymphoproliferative diseases (Lebeau et al., 2002). 
However, the alveolar macrophages stained weakly and non-patchy for IgG, with 
no differential extent of staining in WT versus Hpse
-/- cells (Fig. 4C), suggesting 
that the crystalline bodies seen in Hpse
-/- macrophages do not originate from 
accumulated IgG.  
To further substantiate the association between intracellular Ym1 and crystalline 
formation, we evaluated Ym1 protein levels in both the cell- and fluid- fraction of 
BAL from 13-17 months old mice, using immunoblot analysis. At this age there is 
a significant difference between WT and Hpse
-/- mice in the visual appearance of 
intracellular crystalline material, although a low degree of granulation is also found 
in WT mice (Fig 1C). As shown in figure 4D, high amounts of cell-associated Ym1 
were apparent in three out of four samples collected from Hpse
-/- mice, and only in 
one of three samples collected from WT mice. Notably, the Hpse
-/- sample with low 
levels of Ym1 protein was also given low scores for intracellular granulation (Fig 
4E). In fact, this sample was given the lowest scores within the group of 13-17 
months old Hpse
-/- mice (Fig 1C) and is therefore not a representative sample. 
When analyzing samples from both genotypes, there was a statistically significant 
correlation between intracellular Ym1 levels and the amount of crystalline material 
in BAL cells (Fig 4E). In contrast, extracellular Ym1 levels did not correlate with 
intracellular crystals (Fig 4F) and the levels of Ym1 in cell-free BAL fluid did not 
differ between Hpse
-/- and WT mice (Fig 4D). Collectively, these results strongly 
suggest that heparanase deficiency results in accumulation of Ym1 in airway   16 
macrophages and that Ym1 is the crystal-forming unit in Hpse
-/- alveolar 
macrophages. 
 
3.5. Non-degraded HS chains in bone marrow derived Hpse
-/- macrophages  
The results described above indicate that the absence of heparanase affects the 
homeostasis of alveolar macrophages. To study the possible involvement of 
macrophage HSPGs in this effect, biosynthetic labeling experiments were carried 
out. Because of the low number of macrophages that can be recovered from BAL 
fluid, the biosynthetic labeling experiments were instead performed using 
macrophages derived by in vitro differentiation of bone marrow precursors (bone 
marrow-derived macrophages; BMMØs). As shown in Fig. 5A, cells strongly 
positive for the macrophage marker CD11b were obtained by in vitro 
differentiation of bone marrow precursors in the presence of L929-conditioned 
medium. The numbers of CD11b-positive cells and the intensity of CD11b staining 
did not differ between WT and Hpse
-/- cells, indicating that absence of heparanase 
does not influence macrophage differentiation (Fig 5A). Moreover, staining with 
May-Grünwald/Giemsa did not reveal any obvious morphological difference 
between BMMØs from WT and Hspe
-/- mice (not shown). In contrast to the BAL 
macrophages, no signs of intracellular granulation were seen in Hpse
-/- BMMØs. 
However, as this phenotype appears to be age-dependent (see Fig. 1B and C), its 
absence in BMMØs after 10 days of culture is not unexpected.  
 
Having confirmed the macrophage phenotype of BMMØs (Fig 5A), we 
metabolically labeled the cells with 
35S-sulfate, followed by purification of cell-
associated and secreted HS. Gel filtration analysis showed that HS chains   17 
recovered from both the cell-associated and secreted HS isolated from Hpse
-/- 
BMMØs are longer than HS extracted from WT BMMØs (Fig. 5B), indicating that 
lack of heparanase leads to accumulation of non-degraded HS chains in Hpse
-/- 
BMMØs.    18 
4. Discussion 
 
In the present study we establish that heparanase decisively affects macrophage 
homeostasis. This was demonstrated by the findings that macrophages lacking 
heparanase contain non-degraded HS chains and that alveolar macrophages from 
Hpse
-/- mice exhibit an age-dependent increase in granule-like structures, identified 
as electron dense crystalline bodies surrounded by intracellular membranes. 
Moreover, the altered morphology of Hpse-/- alveolar macrophages was associated 
with an increased patchy staining of intracellular Ym1, a protein known to form 
intracellular crystals (Nio et al., 2004). 
 
Heparanase expression has been detected in a variety of leukocyte populations, 
including monocytes/macrophages, dendritic cells, neutrophils, CD4
+ T cells, mast 
cells and eosinophils (Benhamron et al., 2006; Temkin et al., 2004; Vlodavsky et 
al., 1992). Interestingly, heparanase expressed on the surface of dendritic cells and 
macrophages has been shown to promote migration of these cells, by degrading 
ECM barriers (Benhamron et al., 2006; Sasaki et al., 2004). Moreover, heparanase 
can enhance cell adhesion independent of its enzymatic activity, and thereby 
contribute to cell motility (Goldshmidt et al., 2003; Sotnikov et al., 2004). These 
findings suggest a role for heparanase in regulating leukocyte migration processes. 
We therefore hypothesized that absence of heparanase may lead to defective 
leukocyte migration, possibly resulting in a reduced number of leukocytes in the 
BAL. We show, however, that the absence of heparanase does not influence these 
leukocyte populations adversely. Thus, it appears that under normal conditions 
heparanase expression is not essential for migration of leukocytes in to the   19 
airways. However, it remains to be elucidated whether heparanase influences 
migration of the corresponding cell types during an inflammatory reaction.  
 
A striking and novel finding in this study was the appearance of granulated 
alveolar macrophages in aged mice lacking heparanase, as detected by May 
Grünwald/Giemsa staining. This phenomenon was exclusively seen in the BAL 
macrophage population, and was totally absent in other airway leukocytes and in 
peritoneal macrophages. A closer examination of the macrophages by TEM 
revealed that the granule-like structures had a distinct electron dense needle-shaped 
crystalline appearance. Moreover, the TEM analysis showed that the intracellular 
crystalline bodies were enclosed by membranes. One possible interpretation of 
these findings is that the crystalline bodies are located in lysosomes, and that they 
arise as a consequence of impaired regulation of compounds accumulating in the 
lysosome due to the absence of heparanase. In line with such a possibility, 
heparanase has previously been identified in intracellular compartments, including 
late endosomes and lysosomes (Goldshmidt et al., 2002a) in which proheparanase 
is processed and activated (Zetser et al., 2004). Moreover, heparanase activity is 
optimal at pH5-6 (Gilat et al., 1995), further supporting a physiological function of 
heparanase restricted to cellular compartments having acidic pH, such as 
lysosomes.  
 
An obvious possibility would be that the crystalline bodies in Hpse
-/- macrophages 
contain HSPGs that accumulate in lysosomes as a result of heparanase-deficiency. 
However, since the absence of heparanase did not result in a substantial 
accumulation of cell-associated HSPGs as judged by biosynthetic labeling   20 
experiments and by basic-dye cell staining, it appears less likely that HSPGs are 
predominant components of the crystals. Another possibility is that accumulation 
of crystalline bodies is linked to the marked increase in HS chain length shown to 
accompany the absence of heparanase. Although we cannot precisely explain how 
the increased HS chain length could account for the accumulation of crystalline 
material, one potential scenario could be that abnormally long HS chains may 
serve as a support that accumulates multiple crystal-forming molecules thus 
facilitating crystal formation. This would be in some analogy with the proposed 
contribution of HSPGs to amyloid formation (Stevens and Kisilevsky, 2000).  
 
A crucial issue is to identify the crystal-forming unit in Hpse
-/-alveolar 
macrophages. Here we present several observations suggesting that the chitinase-
like protein Ym1 is a main candidate. Most importantly, we demonstrate a 
statistically significant correlation between the extent of granule-like structures in 
alveolar macrophages and the amounts of intracellular Ym1 in the BAL cell 
fraction. Moreover, there was a markedly increased Ym1 immunostaining in Hpse
-
/- alveolar macrophages as compared to WT counterparts, suggesting an 
intracellular accumulation of Ym1 protein in the absence of heparanase. Notably, 
staining of Ym1 was irregular with several intensely stained regions surrounded by 
non-stained areas, compatible with the presence of Ym1 within membrane-
surrounded organelles. Ym1 exhibits several known features that are in agreement 
with this notion. Firstly, Ym1 is known to easily form crystals in vitro (Chang et 
al., 2001) and intracellular crystalline bodies in vivo (Nio et al., 2004), in particular 
in alveolar macrophages from aged immunodeficient mice (Guo et al., 2000; 
Harbord et al., 2002). Secondly, since HS and heparin are physiological ligands to   21 
Ym1 (Chang et al., 2001), it may be speculated that changes in HS turnover affect 
Ym1 aggregation and crystallization. Finally, Ym1 is selectively expressed by 
alveolar macrophages and immature neutrophils under normal conditions (Nio et 
al., 2004) and is only expressed by peritoneal macrophages upon LPS-stimulation 
(Hung et al., 2002) or differentiation into alternatively activated macrophages 
(Kreider et al., 2007; Rauh et al., 2005). The selective expression of Ym1 in 
alveolar, but not peritoneal macrophages is well in line with the appearance of 
granule-like structures only in the former cell type. Collectively, these findings 
strongly suggest that Ym1 is the crystal-forming unit in Hpse
-/- alveolar 
macrophages. 
 
Ym1 belongs to a group of chitinase-like proteins, including Ym2 and BRP-39 in 
mice, and YKL-40 in humans (Bussink et al., 2007). Increased expression of these 
proteins has been associated with inflammatory diseases, in particular with allergic 
asthma (reviewed in (Lee et al., 2008; Shuhui et al., 2009). The physiological 
function of Ym1 is not clear, but a role in eosinophil chemotaxis (Owhashi et al., 
2000) and promotion of cytokine production (Cai et al., 2009) has been suggested. 
Interestingly, Ym1 has been reported to exhibit a weak ability to cleave N-
acetylglucosamine units (Guo et al., 2000; Harbord et al., 2002), suggesting that 
Ym1 may not only bind to HS but can possibly also cleave HS, and thus function 
in a manner similar to heparanase. However, the ability of Ym1 to process HS 
remains to be established.  
 
In conclusion, the present study indicates that heparanase has a physiological role 
in airway cell homeostasis, by regulating the morphology of alveolar macrophages   22 
and by controlling the levels of intracellular Ym1. Considering the findings 
presented here and the implication of heparanase in inflammatory processes in 
general (Li and Vlodavsky, 2009), it may be anticipated that heparanase has a role 
in the regulation of airway inflammatory diseases.  
 
   23 
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Figure captions 
 
Fig. 1. Effect of heparanase deficiency on airway leukocyte composition and 
morphology. Bronchoalveolar lavage (BAL) cells were collected from Hpse
-/- and 
WT mice of different ages and stained with May-Grünwald/Giemsa. (A) 
Differential counts of BAL leukocytes from 7 months old mice (n=11; pooled from 
3 independent experiments): tot, total cells; mac, macrophages; lym, lymphocytes; 
neu, neutrophils; eos, eosinophils. The graph shows the mean total number of cells 
± SEM. (B) Representative images showing the presence of granule-like material 
in Hpse
-/- alveolar macrophages from 3 (n=3), 7 (n=11; pooled from 3 independent 
experiments) and 13-17 (n=6; pooled from 2 independent experiments) months old 
mice. The extent of granulation was quantified by blinded scoring and the results 
are presented as mean scores ± SEM (C). Statistical differences were determined 
by Mann-Whitney U test: ***, P < 0.001; *, P < 0.05; not significant (ns), P > 
0.05. 
 
Fig 2. Basic dye staining of Hpse
-/- and WT macrophages. Alveolar macrophages 
(AM) and peritoneal macrophages (PM) from 7 months old mice (n=3-4) were 
stained with Alcian blue (A) or Toluidine blue (B) dye. Stained peritoneal mast 
cells (MC) are shown as positive controls. Representative images are shown. ND, 
not done. 400x original magnification. 
 
Fig 3. Transmission electron microscopy (TEM) analysis of alveolar macrophages. 
Upper panels: Representative micrographs showing the morphology of WT and 
Hpse
-/- macrophages. Lower panels: Higher magnification of selected areas marked   31 
by squares in the upper panels. Note the abundance of electron dense crystalline 
material surrounded by membranes (arrows) in the Hpse
-/- macrophage. N, 
nucleus; L, lysosome. Original magnification x 9,000. 
 
Fig. 4. Heparanase deficiency results in increased levels of Ym1 in alveolar 
macrophages. BAL and peritoneal cells were collected from 7 months old WT and 
Hpse
-/- mice (A-C). Cytospin preparations of BAL cells (A, C) and peritoneal cells 
(B) were stained with anti-Ym1 (A, B), anti-IgG heavy and light chains (C), or 
isotype specific control antibodies. Images are representatives of 6 (A) or 2 (B and 
C) independent experiments. BAL cells and cell-free BAL fluid were collected 
from 13-17 months old mice and subjected to SDS-PAGE followed by 
immunoblotting with anti-Ym1 antibodies (D). Band intensities (counts/mm
2) were 
measured and the results are expressed as normalized densitometry values, i.e. 
ratios between samples and the corresponding β-actin loading control (E, F). 
Amounts of intracellular granule-like structures were analyzed by blinded scoring 
of May-Grünwald/Giemsa-stained cells and were plotted against corresponding 
densitometry values (E, F). The degree of granulation was significantly associated 
with intracellular Ym1 levels (E) but not with extracellular Ym1 levels (F) in 
BAL, as determined by Spearman correlation test (P < 0.05).  
 
Fig. 5. Effects of heparanase deficiency on the molecular size of HS isolated from 
bone marrow-derived macrophages (BMMØs). (A) Flow cytometry analysis 
demonstrating that WT and Hpse
-/- BMMØs show equal expression of the 
macrophage marker CD11b. (B) Gel chromatography on Superose 6 was applied   32 
to analyze biosynthetically 
35S-sulfate-labeled secreted (upper panel) and cell-
associated (lower panel) HS from WT and Hpse
-/- BMMØ.  
 Fig.1	


(B) 
(C) 
(A) 
3  7  17 
H
p
s
e
-
/
-
 
W
T
 
tot mac lym neu eos
0
10
20
30
WT
Hpse-/-
B
A
L
 
c
e
l
l
s
 
(
x
1
0
4
)
0.0
0.5
1.0
1.5
2.0
2.5
*** *
WT
Hpse-/-
3 7 13-17
Age of mice (months)
G
r
a
n
u
l
a
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)Fig.2	


(A)  MC  (B)  PM  AM 
H
p
s
e
-
/
-
 
W
T
 
MC  AM 
H
p
s
e
-
/
-
 
W
T
 
ND Fig.3	


WT  Hpse-/- 
N  N 
L 
L? 0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.0
0.5
1.0
1.5
Normalized densitometry
G
r
a
n
u
l
a
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
Fig.4	


Hpse-/-  WT  (A)  Hpse-/-  WT  (B) 
Y
m
1
 
c
o
n
t
r
o
l
 
Y
m
1
 
c
o
n
t
r
o
l
 
Hpse-/-  WT 
I
g
G
 
c
o
n
t
r
o
l
 
(C) 
(D) 
(E)  (F) 
Ym1  
β-actin  
Hpse-/-  WT  Hpse-/-  WT 
BAL cells  BAL fluid 
BAL cells 
Spearman r=0.786 
BAL fluid 
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.0
0.5
1.0
1.5
Normalized densitometry
G
r
a
n
u
l
a
t
i
o
n
 
(
m
e
a
n
 
s
c
o
r
e
)
Hpse-/-
WT
45 kDa  
43 kDa  Fig.5	


Hpse-/- 
WT 
CD11b 
93% 
97% 
(A)  (B) 
0
300
600
900
1200
5 7 9 11 13 15 17 19 21 23
0
300
600
900
WT medium
Hpa-KO medium
14kDa 
3
5
S
 
(
c
.
p
.
m
.
)
 
Elution volume (ml) 
Medium 
Cell 
Hpse-/- 
WT 